CLNN - Clene's mid-stage trial evaluating its COVID-19 treatment fails to meet main goal
- Clene ( NASDAQ: CLNN ) on Tuesday said a phase two study of its zinc and silver solution CNM-ZnAg for the treatment of COVID-19 failed to meet its main goal.
- The mid-stage trial assessed the efficacy and safety of CNM-ZnAg in COVID infected participants in Brazil. Participants randomly received daily a low or high dose of CNM-ZnAg or a placebo.
- The primary endpoint of the study assessed the time to substantial alleviation of COVID symptoms in the trial participants.
- CLNN said no clinical benefit was observed for CNM-ZnAg versus placebo.
- "While COVID has not been a therapeutic focus of the company, we were compelled to explore the potential of CNM-ZnAg to help address the global pandemic. At this time, we will cease further development for COVID," CLNN CEO Rob Etherington said in a statement .
- CLNN stock was marginally higher after hours.
For further details see:
Clene's mid-stage trial evaluating its COVID-19 treatment fails to meet main goal